On Wednesday,Shares of Eli Lilly and Co (NYSE:LLY), added 0.36% and trading at $81.39 in the Current trading session. The current trading range of the stock ranges between $81.28 and $82.09. Eli Lilly and Company (LLY) will present data from several studies which further reinforce the advancement of its diverse clinical cancer portfolio during the European Society of Medical Oncology’s (ESMO) 2016 Congress in Copenhagen, October 7-11. Presentations include new data on abemaciclib, a CDK 4 and CDK 6 inhibitor, and olaratumab, a PDGFRα blocking antibody that recently received a positive CHMP opinion, in addition to data on: pemetrexed, a multi-targeted antifolate; ramucirumab, a VEGF Receptor 2 antagonist; necitumumab, an EGFR blocking antibody; and prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor. Of these presentations, four are featured in late-breaking abstracts (two on abemaciclib, and one each on pemetrexed and ramucirumab).
The presentations on pemetrexed, ramucirumab and necitumumab include data from a few of Lilly’s immuno-oncology clinical collaborations with Merck (known as MSD outside the U.S. and Canada) in trials that are evaluating these molecules in combination with Merck’s pembrolizumab. Notably, the first results from KEYNOTE-021G – which studied pembrolizumab in combination with pemetrexed-plus-carboplatin contrast to pemetrexed-plus-carboplatin alone for the first-line treatment of patients with advanced nonsquamous non-small cell lung cancer regardless of PD-L1 expression – will be featured in the Presidential Symposium on October 9.
DENTSPLY SIRONA Inc (NASDAQ:XRAY), jumped 0.12% and trading at $58.97 in the last trading session. The current trading range of the stock ranges between $58.74 and $59.12. The company’s Market capitalization is $13.70 Billion with the total Outstanding Shares of 233.01 million. DENTSPLY SIRONA Inc. (“Dentsply Sirona”) (XRAY), The Dental Solutions CompanyTM, recently declared that its Board of Directors declared a quarterly cash dividend of $0.0775 per share of common stock, an indicated annual rate of $0.31 per share. The dividend is payable on October 14, 2016 to holders of record on September 30, 2016.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX), gained 2.95% and trading at $24.44 in the current trading session. The current trading range of the stock ranges between $23.70 and $24.56. During the 52-week trading session the minimum price at which share price traded, registered at $18.55 and reached to max level of $179.83. Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) declares its (unaudited) financial report for the eight months ended 31 August 2016. These financial statements are being published to provide all shareholders and shareholders with the most current financial information in order to facilitate a full understanding of the implications of the Company’s recently declared deal to acquire the commercialization rights to RUCONEST® in North America from its partner Valeant and the related projected financing activity.
These results do not replace the quarterly report for the first nine months of 2016, which is because of be published on 27 October 2016.
Sales of RUCONEST® for the period to 31 August were up 48% overall contrast to the six months to 30 June 2016, so that sales in the two months of July and August alone were higher than the whole of the first quarter this year.
Sales in the US to 31 August up by about 28% contrast to the same period last year, and up 43% contrast to the first half year of 2016.
Gross Profit raised by 24% relative to the same period last year, and up 42% contrast to the first half year of 2016.